Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Sunday, 08 August 2021 11:17

Fasheng Li

Written by
I graduated with a master's degree from the Southern Medical University. Now I am a resident of the Cardiothoracic Surgery Center of the Affiliated Hospital of Guangdong Medical University. I am interested in the tumor immune microenvironment with immunotherapy efficacy research and bioinformatics analysis of non-small cell lung cancer.
Sunday, 08 August 2021 11:17

Haiyu Zhou

Written by
Sunday, 08 August 2021 11:17

Baohui Han

Written by
Sunday, 08 August 2021 11:17

Jie Wang

Written by
Director of Internal Medicine, Cancer Hospital Chinese Academy of Medical Sciences
Chief Physician, Professor of Peking Union Medical College
Winner of National "Outstanding Youth" Fund
Leader of the Innovation Team of the Ministry of Education
Vice chairman, Chinese Society of Clinical Oncology (CSCO) Small Lung Cancer Professional Committee
Candidate chairman, Chinese Society of Clinical Oncology (CSCO) Non-small Lung Cancer Professional Committee
Vice Chairman, Chinese Anti-Cancer Association Lung Cancer Professional Committee
Sunday, 08 August 2021 11:17

Zhijie Wang

Written by
Dr Zhijie Wang is a Chief Physician for the National Cancer Center and National Clinical Research Center for Cancer in Beijing, China. He is also Chief Physician, MD Editorial Board Member of the Chinese Society of Clinical Oncology (CSCO) Guidelines for non-small cell lung cancer, member of the National Cancer Quality Control Center and National Anti-tumor Drug Surveillance System, Managing Director of the CSCO, and Vice Chairman of the China Anti-Cancer Association and the China Association for Promotion of Health Science and Technology. Dr Wang has more than 30 SCI publications as first and/or corresponding author, including the Lancet Respiratory Medicine, Journal of Clinical Oncology, JAMA Oncology, PNAS, Cancer Research, Clinical Cancer Research, and JTO. Dr Wang was also selected for the young top-notch talent of the National Ten Thousand Talent Program.
Sunday, 08 August 2021 11:17

Wei Nie

Written by
Dr. Wei Nie is a thoracic oncologist at Shanghai Chest Hospital, Department of Pulmonary Medicine. He is also the member of ASCO, CSCO, ESMO, and IASLC. His clinical and research interests are in molecular immunotherapy and targeted therapy in thoracic malignancies. He has over 60 publications including in Journal of the National Comprehensive Cancer Network, OncoImmunology, and International Journal of Cancer.
Sunday, 08 August 2021 11:17

Li Zhang

Written by
Professor Li Zhang is Professor of Medical Oncology, Director of Medical Oncology Department of Sun Yat-Sen University Cancer Centre (SYSUCC), Deputy Director of Lung Cancer Research Centre of SYSU. He is also the member of ASCO, AACR, ESMO, CSCO, IASLC, MASCC, Member of communication committee of IASLC. He received his medical and master of clinical oncology degrees from SYSU and was board certified as a physician in medical oncology. He has completed training as a visiting fellow at the MD Anderson Cancer Centre, Houston; and Institut Gustave Roussy, Paris, France.

Professor Zhang’s research interest is in the development of molecular, prognostic and therapeutic approaches to improve the care for patients with lung cancer and Nasopharyngeal carcinoma. He is also actively involved in cancer palliative and supportive care like cancer pain management and chemotherapy induced nausea and vomiting (CINV). He contributes extensively to the Chinese Anti-Cancer Association (CACA) where he currently serves as Presidents of the Committee of Rehabilitation and Palliative Care (CRPC), CACA. He is also a standing committee member of the Chinese Society of Clinical Oncology (CSCO) and President-elect of immunotherapy expert committee of CSCO.

Professor Zhang has published more than 200 clinical papers in top-tier journals like: Lancet, Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, JAMA Oncology, Annals of Oncology, Nature communications. He also presented abstracts to many major congresses like ASCO, ESMO, WCLC, MASCC meetings. He is an editorial board member of Clinical Lung Cancer, Cancer Communications, Chinese Journal of Clinical Oncology. At present, he is a senior consultant to the Centre of Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA) and had formerly drafted the CFDA Guidance for Industry: Clinical Trial for the Approval of Cancer Drugs and Biologics (second version, 2006).
Sunday, 08 August 2021 11:17

Wenfeng Fang

Written by
Sunday, 08 August 2021 11:17

Yan Huang

Written by
Sunday, 08 August 2021 11:17

Hongyun Zhao

Written by
Page 324 of 371